2023-04-19 06:51:28 ET
- ANGLE ( OTCQX:ANPCY ) signs an agreement with BioView to develop a liquid biopsy circulating tumor cell (or CTC) HER2 assay for breast cancer.
- It will be utilising ANGLE's FDA cleared Parsortix PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs.
- The company has already successfully integrated BioView's technology in its R&D and clinical laboratories for assay development and pharma services.
For further details see:
ANGLE partners with BioView